Cannabis Based Medicine

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

TEL AVIV, Israel and BETHESDA, Maryland, June 10, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with Cannomed Medical Cannabis Industries Ltd. (TASE: CNMD), to develop cannabis …

Read More »

CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases

SEATTLE and KING of PRUSSIA, Pa., June 2, 2020 /PRNewswire/ — Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases. Initially, the alliance will focus …

Read More »

New Study Shows Cannabis Use for Management of Chronic Musculoskeletal Pain is Increasing

ROSEMONT, Ill., May 19, 2020 /PRNewswire/ — The use of medical cannabis has garnered a lot of recent attention, especially as parts of the United States and Canada have legalized its use. While it has been studied in cancer and nerve pain, not much is known about the usage rate …

Read More »

JAMA Neurology Publishes Results from Positive Phase 3 Trial of Epidiolex Oral Solution in Children with Seizures Associated with Dravet Syndrome

CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results from the second positive Phase 3 …

Read More »

Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 18, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the cannabinoids CBN (Cannabinol) and CBC (Cannabichromene) and their acidic form were shown to have necrotic effects on …

Read More »

Cannabics Pharmaceuticals Collaborates with RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 11, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat …

Read More »

Final Results of Cannabics’ Pilot Study of its Controlled Released Capsules for Treatment of Cancer Anorexia-Cachexia Syndrome Published

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot study to test the efficacy of Cannabics’ Dosage-Controlled capsules for the treatment …

Read More »

Zynerba Announces Positive Data from its Phase 2 Study of its CBD Gel Zygel in Developmental and Epileptic Encephalopathies

DEVON, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced positive top line results from the open label Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel™ …

Read More »

GW Pharma Reports Positive Results from its Phase 3 Trial of Epidiolex in Patients with Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase …

Read More »

INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

PHOENIX, Jan. 09, 2019 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray. These results identified a dose that showed a …

Read More »